Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Published	Pages	Publisher	Report code
Dec 2022	52	Global Markets Direct	ASDR-613965

Published: Dec 2022 - Pages : 52 - Publisher : Global Markets Direct - Report code : ASDR-613965

Aceragen Inc
Amryt Pharma Plc
Astellas Pharma Inc
Cellivery Therapeutics Inc
Jyant Technologies Inc
NeuroNano Pharma Inc
Neurotez Inc
Regeneron Pharmaceuticals Inc
XL-protein GmbH

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drugs In Development, 2021

This report can be of interest as well:

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drugs In Development, 2021

Published: December, 2021 | Report code: ASDR-595777